| 000 | 01543 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250512142316.0 | ||
| 264 | 0 | _c19720615 | |
| 008 | 197206s 0 0 eng d | ||
| 022 | _a0028-3878 | ||
| 024 | 7 |
_a10.1212/wnl.22.4.384 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChase, T N | |
| 245 | 0 | 0 |
_aMethyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism. _h[electronic resource] |
| 260 |
_bNeurology _cApr 1972 |
||
| 300 |
_a384-92 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBlood Pressure |
| 650 | 0 | 4 |
_aBrain _xmetabolism |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 |
_aDihydroxyphenylalanine _xtherapeutic use |
| 650 | 0 | 4 |
_aDopamine _xmetabolism |
| 650 | 0 | 4 | _aEvaluation Studies as Topic |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGastrointestinal Diseases _xetiology |
| 650 | 0 | 4 |
_aHeart _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydrazines _xadverse effects |
| 650 | 0 | 4 |
_aHydroxyindoleacetic Acid _xcerebrospinal fluid |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethyldopa _xadverse effects |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMotor Skills _xdrug effects |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aPhenylacetates _xcerebrospinal fluid |
| 650 | 0 | 4 |
_aSerotonin _xmetabolism |
| 700 | 1 | _aWatanabe, A M | |
| 773 | 0 |
_tNeurology _gvol. 22 _gno. 4 _gp. 384-92 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/wnl.22.4.384 _zAvailable from publisher's website |
| 999 |
_c5065280 _d5065280 |
||